drugset
drugset / Trial / NCT04897139

Flu-Bu-Mel Based Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allo-HSCT

NCT04897139 ↗

Phase 2 Unknown 23 enrolled Shanghai Jiao Tong University School of Medicine
NaSingle-groupOpen-labelTreatment

Summary

In this phase II clinical trial, we evaluate the efficacy and feasibility of conditioning regimen of fludarabine 150mg/m2, busulfan 9.6mg/kg, melphalan 100mg/m2 and etoposide 800mg/m2 in patients with lymphoid malignancies.

Timeline

Start
2021-01-01
Primary completion
2024-06-01
Completion
2024-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Busulfan Small molecule 6.4 mg/kg —
Subject Etoposide Small molecule 600 mg/m2 —
Subject Fludarabine Small molecule 150 mg/m2 —
Subject Melphalan Small molecule 100 mg/m2 —

Indications

lymphoid neoplasm